18 results about "Ketorolac" patented technology

The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative. The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative thereof, for use in a method for the treatment of conjunctivitis and for the prevention or treatment of inflammation or prevention of infection after cataract surgery in a subject, according to a dosage regimen that improves patient compliance and tolerability and enables the prevention and treatment of intermediate / antibiotic-resistant infections.

The present disclosure describes topical ketorolac compositions that comprise a eutectic solvent, such as choline chloride and propylene glycol, and methods and uses thereof. The compositions of the present disclosure are capable of delivering an effective amount of ketorolac through the skin and are believed to be useful in treating inflammation and / or pain, such as gout.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

Provided are a method for preparing (R)-ketorolac and use thereof. The method includes the following steps: step 1, preparing ketorolac; and step 2, subjecting the ketorolac to resolution to obtain the (R)-ketorolac, the resolution being selected from the group consisting of chiral amine resolution and enzyme resolution.

The invention discloses a novel ketorolac synthesis method, which takes 2-(1H-pyrrole-1-yl) propionitrile as a raw material, and ketorolac is obtained through the steps of cyclization reaction, benzoylation reaction, Vanderson reaction, hydrolysis reaction and the like.

Salts of R-ketorolac, including solid salts, such as crystalline salts of the meglumine and tromethamine salts R-ketorolac, are disclosed. Methods of preparing such salts, pharmaceutical compositions comprising salts, and methods of treating cancer with such salts are further provided.

A ketorolaco derivative as shown in formula (I) has a better half-life and stability, has good pharmacokinetic properties, and has a higher stability in vitro; and as a preparation, the ketorolaco derivative can enhance efficacy and reduce toxicity. The present invention well improves the defects of frequent administration, gastrointestinal side effects, poor compliance and the like in traditional ketorolaco preparations.

The present invention relates to a storage-stable pharmaceutical composition for ophthalmic administration in the form of an aqueous solution comprising a therapeutically effective amount of antibiotic levofloxacin or a pharmaceutically acceptable salt or derivative thereof, as a first active ingredient, and a therapeutically effective amount of non-steroidal anti-inflammatory and analgesic ketorolac or a pharmaceutically acceptable salt or derivative thereof, as a second active ingredient, wherein said first active ingredient is from about 0.4 to about 0.9% w / v and said second active ingredient is from about 0.4 to about 0.9% w / v, wherein the weight / volume percentages are expressed as g / 100mL units, in order to prevent the precipitation and improve the stability of the product.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to ketorolac salt of melogabalin and a preparation method of the ketorolac salt. The ketorolac salt of melogabalin provided by the invention is radiated by Cu-K alpha, and an X-ray diffraction spectrum expressed by 2 theta has characteristic peaks at least at the positions of 3.95 + / -0.2 degrees, 4.34 + / -0.2 degrees, 5.19 + / -0.2 degrees, 10.42 + / -0.2 degrees and 14.48 + / -0.2 degrees. The crystal form is good in stability, has remarkably improved dissolving property and pharmacokinetic effect, and is high in patent medicine value; the preparation method is simple to operate, the crystallization process is easy to control, and the reproducibility is good.

The present invention relates to a solid oral pharmaceutical composition comprising ketorolac or one of the salts or derivatives thereof as active ingredient. The composition takes the form of a multi-layer pharmaceutical composition comprising at least one component comprising part of the total amount of ketorolac or one of the salts or derivatives thereof exhibiting prolonged release of the active ingredient and at least one second component comprising the remainder of the total amount of ketorolac or one of the salts or derivatives thereof exhibiting immediate release of the active ingredient. By providing a specific combination of immediate-release and prolonged-release components, it is possible to obtain a composition that provides coordinated release of the drug and improves the analgesic response through the use of ketorolac. The invention also includes the process of preparing such compositions and use thereof in preparing a medicament for pain treatment.

The present application belongs to the technical field of medicine crystallization, and particularly relates to a ketorolac and piperazine co-crystal crystal form and a preparation method thereof. The co-crystal has characteristic peaks at 8.0+ / -0.2°, 9.8+ / -0.2°, 13.5+ / -0.2°, 16.1+ / -0.2°, 17.0+ / -0.2°, 18.3+ / -0.2°, 19.5+ / -0.2°, 19.6+ / -0.2°, 19.9+ / -0.2° and 28.7+ / -0.2° in an X-ray diffraction spectrum expressed in 2θ using Cu-Kα radiation. The co-crystal preparation process is simple, the process is easy to control, the stability is good, the solubility of ketorolac in water is significantly improved, and under the condition of the same prescription, the tablet prepared by taking the co-crystal as an active ingredient has a faster dissolution rate and a higher dissolution degree, and is more suitable for being made into an oral preparation.

To provide methods for inhibiting postoperative inflammatory conditions following ophthalmologic surgical procedures by administering intraocularly during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory drug and an α-1 adrenergic mydriatic agent, such as a liquid irrigation solution of ketorolac and phenylephrine.SOLUTION: In one aspect, there is provided a method for inhibiting a postoperative inflammatory condition following an ophthalmologic surgical procedure, including: identifying a subject with an elevated risk of suffering from a postoperative inflammatory condition; and administering intraocularly to the subject during the ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an α-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier.SELECTED DRAWING: None

The invention provides an aqueous liquid composition for ophthalmic administration, comprising therapeutically effective amounts of a ketorolac compound and of a corticosteroid, wherein the ketorolac compound is present in an essentially dissolved form; wherein the corticosteroid is present in the form of suspended particles; and wherein the composition exhibits an acidic pH of about 6.5 or less. The invention further provides compositions as disclosed herein for use in the prevention or treatment of ocular inflammation and methods for preventing or treating ocular inflammation in a subject.

The technical field that this invention pertains to is pharmaceuticals. The problem that this invention solves is that current over-the-counter migraine / headache medications only treat one symptom which is pain, and current over-the-counter flu products do not address nausea or vomiting which are the most debilitating symptoms of the stomach flu. This invention solves those aforementioned gaps in the market with the addition of an antiemetic to address nausea, vomiting, vertigo, and vestibular symptoms associated with migraines or headaches and the stomach flu. Consumers with migraines or headaches would use this invention if their symptoms included pain, nausea, vomiting, vertigo, or any other vestibular symptoms such as phonophobia or photophobia. Consumers with the stomach flu would use this invention if their symptoms included any of the usual flu symptoms such as fever, pain, body aches, but also with nausea and vomiting which is the key difference compared to existing flu products currently on the market. This invention is new because no prior art discusses using any antiemetics by themselves as a single entity medication or in combination with an analgesic(s) including but not limited to: (1) acetaminophen with or without caffeine and with or without aspirin, (2) acetaminophen with ibuprofen; (3) acetaminophen with naproxen, (4) aspirin, (5) naproxen, and (6) ibuprofen; (7) ketorolac; for the indication of nausea with or without vomiting; vertigo such as migraine-associated vertigo, photophobia, phonophobia, and with or without pain. Additionally, this invention also differs from prior art in that antiemetics can be used in any combination with the aforementioned analgesic(s), and are also able to combined with or without a nasal decongestant such as phenylephrine including any newly reformulated version(s ) of phenylephrine and / or pseudoephedrine with or without dextromethorphan hydrobromide or dextromethorphan polistirex; and with or without guaifenesin. The interchangeability of the drugs and doses allows for versatility which prior art does not offer. Actual dosages used will be within that range at therapeutic, efficacious, and safe dosages in said subjects for the treatment of the indication(s) being claimed and / or exhibited by said subjects at appropriate dosing intervals. Utilizing subtherapeutic and supratherapeutic doses in the ranges are not obvious or usual doses utilized by a person knowledgeable in the prior art, therefore differentiating it from prior art and supporting patentability.

The present invention relates to the technical field of pharmaceutical cocrystals, and in particular to a milrinone-ketorolac cocrystal and a preparation method thereof. The cocrystal is formed by combining milrinone and ketorolac in a molar ratio of 1:1. Using Cu-Kα radiation, an X-ray diffraction spectrum represented by 2θ has characteristic peaks at 7.9±0.2°, 13.3±0.2°, 15.7±0.2°, 15.8±0.2°, and 17.8±0.2°. The milrinone-ketorolac cocrystal provided by the present invention has good stability and high solubility, and the preparation method is simple and easy, low in cost, and convenient for large-scale production.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a method for synthesizing a key intermediate of ketorolac. The method involves reacting 2-benzoylpyrrole with triethyl methanetricarboxylate in the presence of tert-butanol peroxide, potassium iodide, cuprous iodide, and tetrabutylammonium iodide, followed by post-treatment to yield 5-benzoylpyrrole-2-methanetricarboxylate triethyl ester (M-1). The reaction conditions are mild, the operation is simple, the reaction steps are few, and the product yield and purity are high, making it suitable for industrial-scale production. It avoids the problem of large amounts of manganese ions and acetic acid present in the system in existing technologies.

Provided are a method for preparing (R)-ketorolac and use thereof, belonging to the technical field of organic synthesis. The method includes the following steps: step 1, preparing ketorolac; and step 2, subjecting the ketorolac to resolution to obtain the (R)-ketorolac, the resolution being selected from the group consisting of chiral amine resolution and enzyme resolution. In the disclosure, glacial acetic acid is used as a reaction solvent, which is not only clean and environmental-friendly, but also easy to be removed. The glacial acetic acid could significantly improve a conversion rate of SM1 as a raw material, thereby improving the yield and the purity of the ketorolac, such that the ketorolac has a yield of not less than 70% and a purity of not less than 99%. The ketorolac is subjected to chiral resolution by the chiral amine or the enzyme to obtain the (R)-ketorolac with a high purity and a high yield, and the (R)-ketorolac could prevent chemotherapy resistance and improve both chemotherapeutic efficacy and cure rate.